Bicycle Therapeutics plc (BCYC): יתרות המזומנים של החברה

BCYC (Bicycle Therapeutics plc) - סמל מסחרי של החברה

Bicycle Therapeutics (BCYC) faces a lack of profitability and a dependence on external financing. The cash reserve dynamics on GURU.Markets show that 0.47 serves as the current liquidity metric. Business development relies on licensing payments and data from the small molecule platform. The project's future depends on FDA approval and the influx of R&D capital into the targeted oncology sector.

BCYC - יתרות המזומנים של החברה Bicycle Therapeutics PLC בטווח 04.07.2022 - 21.11.2026

פילוחי מדדים ואנליטיקה של חברת Bicycle Pharma (BCYC)

- שווי מניות ותחזית קונצנזוס למחירים:
ניתוח כל מדדי החברה:bicycletherapeutics.com
פריט של המותג Bicycle Therapeutics PLC

This indicator measures the business's immediate solvency by tracking the daily volume of liquid assets used to bridge temporary gaps between quarterly reports. An analysis of current cash reserves allows for an assessment of the ability of Bicycle Therapeutics (BCYC) to fund costly peptide clinical trials amid a high burn rate, confirming that reserves are sufficient to sustain operations until the next partner tranches are received.